Payment overview · 2025
General Payments
$153.13
8 reported records · 4 companies
Healthcare provider profile · identity verified
David Bein Eskind, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1902162431
Verified facts
What the public records show
CMS Open Payments records show David Bein Eskind, M.D. received $153.13 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 46.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.65 | 46.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.45 | 27.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.13 | 14.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.90 | 12.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.13 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 879 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 565 | 165 |
| Lisinopril | Lisinopril | 557 | 168 |
| Losartan Potassium | Losartan Potassium | 405 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 391 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 121 |
| Omeprazole | Omeprazole | 302 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 82 |
| Alprazolam | Alprazolam | 246 | 48 |
| Simvastatin | Simvastatin | 233 | 70 |
| Meloxicam | Meloxicam | 227 | 71 |
| Furosemide | Furosemide | 221 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 62 |
| Pregabalin | Pregabalin | 202 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 65 |
| Gabapentin | Gabapentin | 194 | 51 |
| Trazodone Hcl | Trazodone Hcl | 192 | 57 |
| Sertraline Hcl | Sertraline Hcl | 156 | 43 |
| Ozempic | Semaglutide | 155 | 24 |
| Eliquis | Apixaban | 149 | 34 |
| Tramadol Hcl | Tramadol Hcl | 143 | 27 |
| Allopurinol | Allopurinol | 139 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 43 |
| Ezetimibe | Ezetimibe | 130 | 42 |
| Famotidine | Famotidine | 128 | 40 |
| Carvedilol | Carvedilol | 127 | 40 |
| Metformin Hcl Er | Metformin Hcl | 126 | 40 |
| Montelukast Sodium | Montelukast Sodium | 116 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 37 |
| Atenolol | Atenolol | 111 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 39 |
| Potassium Chloride | Potassium Chloride | 106 | 35 |
| Bupropion Xl | Bupropion Hcl | 104 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 27 |
| Metformin Hcl | Metformin Hcl | 103 | 34 |
| Alendronate Sodium | Alendronate Sodium | 102 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 102 | 35 |
| Buspirone Hcl | Buspirone Hcl | 98 | 32 |
| Spironolactone | Spironolactone | 98 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 29 |
| Farxiga | Dapagliflozin Propanediol | 89 | 20 |
| Lorazepam | Lorazepam | 89 | 14 |
| Mounjaro | Tirzepatide | 89 | 17 |
| Glimepiride | Glimepiride | 84 | 26 |
| Prednisone | Prednisone | 80 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 78 | 26 |
| Clonazepam | Clonazepam | 77 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 24 |
| Finasteride | Finasteride | 69 | 22 |
| Azithromycin | Azithromycin | 67 | 62 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 59 |
| Synthroid | Levothyroxine Sodium | 66 | 18 |
| Diazepam | Diazepam | 65 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Methylprednisolone | Methylprednisolone | 60 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 16 |
| Celecoxib | Celecoxib | 56 | 17 |
| Myrbetriq | Mirabegron | 56 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 15 |
| Acyclovir | Acyclovir | 48 | 12 |
| Estradiol | Estradiol | 48 | 15 |
| Donepezil Hcl | Donepezil Hcl | 47 | 19 |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Xarelto | Rivaroxaban | 44 | 11 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 26 |
| Glipizide | Glipizide | 40 | 13 |
| Lovastatin | Lovastatin | 40 | 12 |
| Propranolol Hcl | Propranolol Hcl | 40 | 15 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | 11 |
| Temazepam | Temazepam | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Valsartan | Valsartan | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | 12 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Indapamide | Indapamide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Primidone | Primidone | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Desloratadine | Desloratadine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Testosterone | Testosterone | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.13 · 8 records | PFIZER INC. | ABRYSVO, COMIRNATY, FARXIGA, NURTEC ODT, PREVNAR 20, SHINGRIX, UNITHROID, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error